Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPhA makes appointment

This article was originally published in Scrip

Executive Summary

The US generics group, GPhA, has named Charles Kinney executive vice-president, responsible for internal operations. He joins from the law firm Winston and Strawn, where he headed the federal governmental relations and regulatory affairs practice group. The GPhA also promoted Shawn Brown to vice-president of state government affairs. He has served as director of policy for the past three years.

You may also be interested in...



Accelerated Approval Withdrawals Through The Years

Unlike AMAG's Makena, nearly all the products that have seen their accelerated approvals pulled have left the market quietly, our infographic shows.

Gene Therapy Approval Standards: Available Treatments Influence US FDA’s View On Durability

CBER’s Peter Marks says agency assesses the importance of durability of effect differently for a gene therapy that treats a disease that has no other available therapies versus a condition for which there are multiple approved treatments. Marks’ comments shed more light on the complete response letter for BioMarin’s hemophilia gene therapy Roctavian.

Alkermes’ Antipsychotic Clears US FDA Panel Amid Calls For Broader Professional Education Plan

Communication and education on samidorphan’s opioid antagonistic effects should focus on health care providers that prescribe opioids as well as psychiatrists that prescribe olanzapine, advisory committee says in endorsing the safety and efficacy of ALKS 3831.

UsernamePublicRestriction

Register

OM006764

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel